Tunlametinib: First Approval

Keam, Susan J.

doi:10.1007/s40265-024-02072-x

Drugs

2024

DOI: 10.1007/s40265-024-02072-x

|View full text |Cite

Tunlametinib: First Approval

Susan J. Keam

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Yang,

2024

J Hematol Oncol

View full text Add to dashboard Cite

Variants in the RAS family (HRAS, NRAS and KRAS) are among the most common mutations found in cancer. About 19% patients with cancer harbor RAS mutations, which are typically associated with poor clinical outcomes. Over the past four decades, KRAS has long been considered an undruggable target due to the absence of suitable small-molecule binding sites within its mutant isoforms. However, recent advancements in drug design have made RAS-targeting therapies viable, particularly with the approval of direct KRAS G12C inhibitors, such as sotorasib and adagrasib, for treating non-small cell lung cancer (NSCLC) with KRAS G12C mutations. Other KRAS-mutant inhibitors targeting KRAS G12D are currently being developed for use in the clinic, particularly for treating highly refractory malignancies like pancreatic cancer. Herein, we provide an overview of RAS signaling, further detailing the roles of the RAS signaling pathway in carcinogenesis. This includes a summary of RAS mutations in human cancers and an emphasis on therapeutic approaches, as well as de novo , acquired, and adaptive resistance in various malignancies. Supplementary Information The online version contains supplementary material available at 10.1186/s13045-024-01631-9.

show abstract

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Yang,

2024

J Hematol Oncol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tunlametinib: First Approval

Cited by 1 publication

References 11 publications

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms

Contact Info

Product

Resources

About